ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO1073

The Efficacy and Safety of SGLT2 Inhibitors and GLP1 Receptor Agonists in Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical


  • Sridhar, Vikas, University Health Network, Toronto, Ontario, Canada
  • Zelderloo, Maïté, Katholieke Universiteit Leuven, Leuven, Flanders, Belgium
  • Li, Yanhong, University Health Network, Toronto, Ontario, Canada
  • Cherney, David, University Health Network, Toronto, Ontario, Canada
  • Singh, Sunita K., University Health Network, Toronto, Ontario, Canada

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) decrease adverse cardiorenal outcomes in the general population. We aimed to evaluate the efficacy and safety of SGLT2i and GLP1RA monotherapy and combination therapy in kidney transplant recipients (KTR).


This was a retrospective cohort study of all adult KTR started on SGLT2i and/or GLP1RA between January 1, 2000 and December 31, 2021. Baseline characteristics, drug safety/tolerability, estimated glomerular filtration rate (eGFR), and cardiorenal outcomes were collected.


Of 227 patients analyzed, 78 were on SGLT2i, 79 on GLP1RA and 70 on combination therapy. 120 patients had pretransplant diabetes (DM) (53.6%) and 103 had post-transplant DM (46.0%). Compared to the period before drug initiation, there were no differences in rates of CV events and graft failure with either monotherapy or combination therapy. After one month, SGLT2 inhibition resulted in a median eGFR decline of 6 ml/min/1.73m2 (interquartile range -11 to 3.5) (Figure 1). Drug discontinuation was high, with 19.2% of SGLT2i users, 28.7% of GLP1RA and 41.4% on combination therapy stopping therapy – ‘hospitalization’ with SGLT2i and ‘intolerance’ with GLP1RA and combination therapy were the most frequent causes of discontinuation. However, compared to the period before drug initiation, rates of urinary tract infections, ketoacidosis, acute kidney injury and hepato-pancreato-biliary complications were not significantly different.


SGLT2i, GLP-1RA and combination therapy appear to be safe in KTR, though drug discontinuation is relatively common. The acute eGFR ‘dip’ observed with SGLT2 inhibition suggests tubular-glomerular mechanisms are intact in this unique population.